Morgan Stanley Knock-Out Bavarian.../ DE000MG4A9B1 /
| 2024-12-27 9:08:26 PM | Chg.+0.100 | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.710EUR | +16.39% | - Bid Size: - |
- Ask Size: - |
- | 138.6633 DKK | 2078-12-31 | Call |
GlobeNewswire
08-16
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
GlobeNewswire
08-13
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
GlobeNewswire
08-08
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vac...
GlobeNewswire
06-26
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to...
GlobeNewswire
06-17
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
GlobeNewswire
05-31
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Sm...
GlobeNewswire
05-07
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
04-29
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
02-23
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire
2023-11-09
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2023-09-21
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
